We are always looking to increase our own development portfolio through in-licensing and partnership agreements.

There are many advantages of partnering with PGXIS, because of our focus in disease areas where pharmacogenomic determination is confirmed.

As pharmacogenomics has been shown to reduce attrition in drug development, we are keen to identify compounds that have failed in clinical studies so that we can apply our expertise to re-activate these programmes.

We want to make an impact in oncology and neurology, and many other therapeutic areas where modern genetics has established key genes important for the disease aetiology, such as type II diabetes and obesity. We also want to be involved in diseases with childhood onset.

Please contact us so we can meet to discuss your compounds and your ideas.
Advantages of Partnering with PGXIS
Partnering with or out-licensing to PGXIS during drug discovery and development has distinct advantages:
  •   PGX in Phase I studies to ensure correct dosing in proof of concept studies
  •   Design of Phase II proof of concept studies incorporating PGx to maximise the opportunity of showing efficiency.
    • Together, application of pharmacogenomics can maximise the chance of showing efficiency in the critical Phase II studies, which are typically the largest source of attrition in the drug development pipeline.